PReCePT2
Reducing brain injury through improving uptake of magnesium
sulphate in preterm deliveries
Chief Investigator
|
Institution
|
Dates
|
Funding Stream
|
Grant Ref
|
Amount
|
|
Dr Karen Luyt
|
University of Bristol
|
01/12/2017 - 30/11/2020 (36 months)
|
Health Foundation Scaling Up Improvement
|
557668
|
£500,000
|
Summary
Preterm birth is the leading cause of brain injury and Cerebral
Palsy (CP) with lifelong impact on children and families.
Magnesium sulphate (MgSO4) given to mothers during
preterm birth is an effective treatment for protecting the babies'
brain. High quality evidence suggests that CP can be reduced in a
third of cases.
TWO THIRDS of UK premature babies are not receiving the benefit
of this highly cost-effective treatment. The dose costs
approximately £1.
A QI package, PReCePT1, was co-designed with patients and staff
and implemented across 5 maternity units in West-England,
increasing average uptake from 21% to 85%.
PReCePT2 will scale this work to 10 maternity units and evaluate
the effectiveness of a supported versus a self-engaged
implementation in a prospective comparison. All teams will receive
training, PReCePT2 resources and time to train their colleagues.
The supported units will also have structured input from a QI-Coach
and funded time to micro-coach their local teams. Routinely
collected data will be used to evaluate impact of the
intervention.
The objective is optimal uptake of MgSO4 in preterm deliveries;
and ultimately a reduction in brain injury. Comparative evidence
between the two adoption models will inform the method of optimal
future UK spread.
Links to further information
https://www.health.org.uk/programmes/scaling-improvement/projects/precept2-reducing-brain-injury-through-improving-uptake
